BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 15816993)

  • 1. Increased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosis.
    Kuo HT; Kuo MC; Chiu YW; Chang JM; Guh JY; Chen HC
    Eur J Clin Invest; 2005 Apr; 35(4):245-50. PubMed ID: 15816993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of C4d expression and staining patterns by immunohistochemistry in renal biopsy samples with focal segmental glomerulosclerosis and minimal change disease.
    Abedi M; Nili F; Dehkhoda F; Abdollahi A; Salarvand S
    Ann Diagn Pathol; 2024 Jun; 70():152281. PubMed ID: 38417352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Study on Complement Activation Distinguishes Focal Segmental Glomerulosclerosis from Minimal Change Disease.
    Cambier A; Patey N; Royal V; Gougeon F; Genest DS; Brachemi S; Bollée G; Merlen C; Bonnefoy A; Lapeyraque AL; Troyanov S
    Kidney Int Rep; 2024 Mar; 9(3):661-670. PubMed ID: 38481495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferroptosis is involved in focal segmental glomerulosclerosis in rats.
    Shi Y; Shi X; Zhao M; Zhang Y; Zhang Q; Liu J; Duan H; Yang B; Zhang Y
    Sci Rep; 2023 Dec; 13(1):22250. PubMed ID: 38097813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.
    Mirioglu S; Daniel-Fischer L; Berke I; Ahmad SH; Bajema IM; Bruchfeld A; Fernandez-Juarez GM; Floege J; Frangou E; Goumenos D; Griffith M; Moran SM; van Kooten C; Steiger S; Stevens KI; Turkmen K; Willcocks LC; Kronbichler A
    Nephrol Dial Transplant; 2024 Mar; 39(4):569-580. PubMed ID: 38341276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary matrix metalloproteinase-7 is a sensitive biomarker to evaluate renal tubular injury in patients with minimal change disease and focal segmental glomerulosclerosis.
    Yin DY; Hou GL; Yang XQ; Bi LL; Mei XF; Bai MK; Zhou L; Zhu S; Huang YJ
    Clin Kidney J; 2024 Jan; 17(1):sfad027. PubMed ID: 38186883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-Related Quality of Life in Focal Segmental Glomerular Sclerosis and Minimal Change Disease: A Qualitative Study of Children and Adults to Inform Patient-Reported Outcomes.
    Carlozzi NE; Massengill SF; Trachtman H; Walsh L; Singhal N; LaVigne JM; Miner JA; Desmond HE; Lynam C; Gipson DS
    Kidney Med; 2021; 3(4):484-497.e1. PubMed ID: 34401716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy.
    Chang JM; Kuo MC; Kuo HT; Chiu YW; Chen HC
    J Lab Clin Med; 2005 Oct; 146(4):210-5. PubMed ID: 16194682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catalpol Attenuates Oxidative Stress and Inflammation via Mechanisms Involving Sirtuin-1 Activation and NF-κB Inhibition in Experimentally-Induced Chronic Kidney Disease.
    Zaaba NE; Al-Salam S; Beegam S; Elzaki O; Yasin J; Nemmar A
    Nutrients; 2023 Jan; 15(1):. PubMed ID: 36615896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in Primary Focal Segmental Glomerulosclerosis in Optimal Diagnostic-Therapeutic Strategy.
    Musiała A; Donizy P; Augustyniak-Bartosik H; Jakuszko K; Banasik M; Kościelska-Kasprzak K; Krajewska M; Kamińska D
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial Endothelin Receptor A Expression Is Associated With Podocyte Injury and Oxidative Stress in Patients With Focal Segmental Glomerulosclerosis.
    van de Lest NA; Bakker AE; Dijkstra KL; Zandbergen M; Heemskerk SAC; Wolterbeek R; Bruijn JA; Scharpfenecker M
    Kidney Int Rep; 2021 Jul; 6(7):1939-1948. PubMed ID: 34307988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High neutrophil/lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease.
    Yoshitomi R; Nakayama M; Sakoh T; Fukui A; Katafuchi E; Seki M; Tsuda S; Nakano T; Tsuruya K; Kitazono T
    Ren Fail; 2019 Nov; 41(1):238-243. PubMed ID: 30942116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood urea nitrogen is independently associated with renal outcomes in Japanese patients with stage 3-5 chronic kidney disease: a prospective observational study.
    Seki M; Nakayama M; Sakoh T; Yoshitomi R; Fukui A; Katafuchi E; Tsuda S; Nakano T; Tsuruya K; Kitazono T
    BMC Nephrol; 2019 Apr; 20(1):115. PubMed ID: 30940101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.
    Florens N; Calzada C; Lyasko E; Juillard L; Soulage CO
    Toxins (Basel); 2016 Dec; 8(12):. PubMed ID: 27999257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of redox modulating NRF2 activators on chronic kidney disease.
    Choi BH; Kang KS; Kwak MK
    Molecules; 2014 Aug; 19(8):12727-59. PubMed ID: 25140450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal biopsy: use of biomarkers as a tool for the diagnosis of focal segmental glomerulosclerosis.
    Aparecida da Silva C; Molinar Mauad Cintra M; de Castro Côbo E; Vinícius da Silva M; Bichuette Custódio F; Rosa Miranda Corrêa R; Roberto Castellano L; Antônia dos Reis M; Reis Machado J
    Dis Markers; 2014; 2014():192836. PubMed ID: 24719498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical cardiovascular disease and its association with risk factors in children with steroid-resistant nephrotic syndrome.
    Candan C; Canpolat N; Gökalp S; Yıldız N; Turhan P; Taşdemir M; Sever L; Çalışkan S
    Pediatr Nephrol; 2014 Jan; 29(1):95-102. PubMed ID: 24037224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease.
    Kennedy DJ; Tang WH; Fan Y; Wu Y; Mann S; Pepoy M; Hazen SL
    J Am Heart Assoc; 2013 Apr; 2(2):e000104. PubMed ID: 23557751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of molecular mechanism of nephrotic syndrome.
    Machado JR; Rocha LP; Neves PD; Cobô Ede C; Silva MV; Castellano LR; Corrêa RR; Reis MA
    Int J Nephrol; 2012; 2012():937623. PubMed ID: 22844593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of olmesartan on arterial stiffness in rats with chronic renal failure.
    Chuang YC; Wu MS; Su YK; Fang KM
    Cardiovasc Diabetol; 2012 Jun; 11():66. PubMed ID: 22694778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.